Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Tobacco Use Disorder 1Smoking Cessation 1Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Squamous Cell 1Neoplasms, Basal Cell 1Melanoma 1Lung Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Behavior 1

Interventions

Cisplatin 76Radiotherapy 44pembrolizumab 39Cetuximab 38Paclitaxel 34Carboplatin 33Docetaxel 30Fluorouracil 25Radiotherapy, Intensity-Modulated 22Nivolumab 18Drug Therapy 14Radiation 12Erlotinib Hydrochloride 9cemiplimab 8Magnetic Resonance Spectroscopy 8130-nm albumin-bound paclitaxel 8durvalumab 7atezolizumab 7Cyclophosphamide 7Afatinib 7Surgical Procedures, Operative 6Panitumumab 6Leucovorin 6Chemoradiotherapy 6fludarabine 5aldesleukin 5Radiosurgery 5Oxaliplatin 5Methotrexate 5Gemcitabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Squamous Cell × Risk Factors × Clear all
NCT03509467 2025-12-19

Using MC1R Genotype to Impact Melanoma Risk Behavior

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
2,054 enrolled 92 charts
Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms, Neoplasms, Basal Cell, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡